Market Access News | pharmaphorum

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

News

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

News

Hundreds of women with locally advanced cervical cancer are to be offered MSD's Keytruda on the NHS in England, thanks to new NICE guidance.

News

Ionis' Tryngolza has been approved for severe hypertriglyceridaemia, opening the door to what the company thinks could be a $3bn market opportunity.

News

New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.

News

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.